JPS6483025A - Blended preparation of drug-resistant live bacterium agent for controlling intestinal function and antibacterial agent - Google Patents

Blended preparation of drug-resistant live bacterium agent for controlling intestinal function and antibacterial agent

Info

Publication number
JPS6483025A
JPS6483025A JP62239731A JP23973187A JPS6483025A JP S6483025 A JPS6483025 A JP S6483025A JP 62239731 A JP62239731 A JP 62239731A JP 23973187 A JP23973187 A JP 23973187A JP S6483025 A JPS6483025 A JP S6483025A
Authority
JP
Japan
Prior art keywords
agent
live bacterium
resistant
intestinal function
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP62239731A
Other languages
Japanese (ja)
Inventor
Fujio Hayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP62239731A priority Critical patent/JPS6483025A/en
Publication of JPS6483025A publication Critical patent/JPS6483025A/en
Pending legal-status Critical Current

Links

Abstract

PURPOSE:To obtain the titled preparation useful for improving bacteria in the intestine, having stable effects, without administering an unnecessary resistant live bacterium, by previously blending a live bacterium agent for controlling intestinal function, showing resistance to a specific antimicrobial agent with the antimicrobial agent. CONSTITUTION:For example, a live bacterium agent for controlling intestinal function, showing resistance to antimicrobial agent such as penicillin drug or synthetic penicillin drug (e.g. oxacillin, cloxacillin or ampicillin) is blended with the antimicrobial agent. Streptococcus (Enterococcus) faecalis or Streptococcus lactis may be cited as the resistant live bacterium. Lactobacillus sporogenes, a kind of Bacillus coagulans, forms a spore and has possibility of use for the same purpose of the resistant bacteria. These useful bacteria are advantageously used.
JP62239731A 1987-09-24 1987-09-24 Blended preparation of drug-resistant live bacterium agent for controlling intestinal function and antibacterial agent Pending JPS6483025A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP62239731A JPS6483025A (en) 1987-09-24 1987-09-24 Blended preparation of drug-resistant live bacterium agent for controlling intestinal function and antibacterial agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP62239731A JPS6483025A (en) 1987-09-24 1987-09-24 Blended preparation of drug-resistant live bacterium agent for controlling intestinal function and antibacterial agent

Publications (1)

Publication Number Publication Date
JPS6483025A true JPS6483025A (en) 1989-03-28

Family

ID=17049091

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62239731A Pending JPS6483025A (en) 1987-09-24 1987-09-24 Blended preparation of drug-resistant live bacterium agent for controlling intestinal function and antibacterial agent

Country Status (1)

Country Link
JP (1) JPS6483025A (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589168A (en) * 1991-04-08 1996-12-31 Unilever Patent Holdings B.V. Probiotic
US5902578A (en) * 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
WO2000010582A3 (en) * 1998-08-24 2000-07-13 Ganeden Biotech Inc Probiotic, lactic acid-producing bacteria and uses thereof
US6306391B1 (en) 1997-03-27 2001-10-23 Cadila Pharmaceuticals, Ltd. Preparation of an oral pharmaceutical formulation containing an anti-infective agent and a microorganism
JP2008511622A (en) * 2004-08-30 2008-04-17 アレキサンドロビッチ キセレフ，ニコライ Orally administrable antibacterial composition
US7632520B2 (en) * 2004-02-16 2009-12-15 Sanjeev Khandelwal Synergistic antibacterial formulation and to a method of making the same
US9622502B2 (en) 2008-10-16 2017-04-18 Ganeden Biotech, Inc. Probiotic Bacillus pasta compositions
US9757442B2 (en) 2009-04-29 2017-09-12 Ganeden Biotech, Inc. Inactivated bacterial cell formulation
US10111916B2 (en) 2003-12-05 2018-10-30 Ganeden Biotech, Inc. Compositions comprising Bacillus coagulans spores and whey
US10383342B2 (en) 2007-08-29 2019-08-20 Ganeden Biotech, Inc. Baked goods
US11235008B2 (en) 2011-03-31 2022-02-01 Ganeden Biotech, Inc. Probiotic sports nutrition compositions

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728380A (en) * 1991-04-08 1998-03-17 Unilever Patent Holdings B.V. Priobiotic containing enterococcus faecium strain NCIMB 40371
US5589168A (en) * 1991-04-08 1996-12-31 Unilever Patent Holdings B.V. Probiotic
US5902578A (en) * 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
US6306391B1 (en) 1997-03-27 2001-10-23 Cadila Pharmaceuticals, Ltd. Preparation of an oral pharmaceutical formulation containing an anti-infective agent and a microorganism
US7807151B2 (en) 1998-08-24 2010-10-05 Ganeden Biotech, Incorporated Probiotic, lactic acid-producing bacteria and uses thereof
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US7708988B2 (en) 1998-08-24 2010-05-04 Ganeden Biotech, Incorporated Probiotic, lactic acid-producing bacteria and uses thereof
WO2000010582A3 (en) * 1998-08-24 2000-07-13 Ganeden Biotech Inc Probiotic, lactic acid-producing bacteria and uses thereof
US8097247B2 (en) 1998-08-24 2012-01-17 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US8187590B2 (en) 1998-08-24 2012-05-29 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
JP2002523372A (en) * 1998-08-24 2002-07-30 ガネデン バイオテック， インコーポレイテッド Symbiotic lactic acid producing bacteria and uses thereof
US10111916B2 (en) 2003-12-05 2018-10-30 Ganeden Biotech, Inc. Compositions comprising Bacillus coagulans spores and whey
US7632520B2 (en) * 2004-02-16 2009-12-15 Sanjeev Khandelwal Synergistic antibacterial formulation and to a method of making the same
JP2008511622A (en) * 2004-08-30 2008-04-17 アレキサンドロビッチ キセレフ，ニコライ Orally administrable antibacterial composition
US10383342B2 (en) 2007-08-29 2019-08-20 Ganeden Biotech, Inc. Baked goods
US10321704B2 (en) 2008-10-16 2019-06-18 Ganeden Biotech, Inc. Probiotic grain-based compositions
US9622502B2 (en) 2008-10-16 2017-04-18 Ganeden Biotech, Inc. Probiotic Bacillus pasta compositions
US11419355B2 (en) 2008-10-16 2022-08-23 Ganeden Biotech, Inc. Probiotic grain-based compositions
US9757442B2 (en) 2009-04-29 2017-09-12 Ganeden Biotech, Inc. Inactivated bacterial cell formulation
US11235008B2 (en) 2011-03-31 2022-02-01 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
US11351206B2 (en) 2011-03-31 2022-06-07 Ganeden Biotech, Inc. Probiotic sports nutrition compositions

Similar Documents

Publication Publication Date Title
Murray Vancomycin-resistant enterococci
HUP9802525A1 (en) Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections
FI964681A (en) Lactobacillus strains of human origin, preparations containing them and their uses
ATE304366T1 (en) PHARMACEUTICAL FORMULATION CONTAINING LACTOBACILLUS CASEI RHAMNOSUS
CY1108646T1 (en) LACTIC ACID BACTERIUM BACTERIA FOR TREATMENT OF BACTERIAL INFECTIONS WITH SIDS
DE69530124D1 (en) LIPOSOMAL ANTIBACTERIAL COMPOSITION WITH LOW STRENGTH
JPS6483025A (en) Blended preparation of drug-resistant live bacterium agent for controlling intestinal function and antibacterial agent
BR9916062A (en) Oral administration of lactobacillus for the treatment and prevention of urogenital infection
GEP20053429B (en) 3-Aminoquinazolin-2,4-Dione, Pharmaceutical Composition Containing Them and Use Thereof as Antibacterial Agents
ATE221783T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING LACTOBACILLUS PLANTARUM AND ARGININE
ES8800160A1 (en) 5,6-Difluoronaphthyridines and 5,6,8-trifluoro-quinolines as antibacterial agents.
WO1997040072A3 (en) Adam proteins and uses thereof
EP1019084A4 (en) Novel antimicrobial polypeptide and methods of use
DK312688A (en) GLYKKOPEPTID antibiotics
ATE108651T1 (en) ACTIVE AGENT: HIGH RATIO LIPID COMPLEX.
Lee et al. Norfloxacin: its potential in clinical practice
TW365538B (en) Pharmaceutical composition for preventing a bacterial disease of fishes and crustaceans
Soriano et al. Effect of Bacteroides fragilis on mortality induced by Escherichia coli in an experimental infection treated with cefotaxime, aztreonam or gentamicin
Giacchino et al. Recurrent sepsis by Salmonella dublin.
MX9708385A (en) Novel tetracycline derivatives.
sameer Mohammed et al. Study effect of antimicrobial against the biofilm associated staphylococcus aureus
Hachimori Fecal bacterial flora under circumstances of prevailing multi-drug resistant bacteria. 2. Changes in fecal bacterial flora and drug-resistance of E. coli and Klebsiella after administration of antibiotics in infant diarrhea
RU95118193A (en) STRAIN OF BIFIDOBACTERIUM COTURNIX BACTERIA USED FOR PREPARATION OF A PROBIOTIC DRUG FOR POULTRY AND VETERINARY
UA31364A (en) The method for treatment of intestinal dysbacteriosis for patients with acute pyelonephritis
GEP19991603B (en) Iersinia Enterocolitica Bacteriophage Strain Consortium